▶주메뉴 바로가기
▶본문 바로가기
South Korean biopharmaceutical firm Celltrion said Nov. 26 that its drug Remsima SC for the treatment of autoimmune diseases has won sales approval in Europe. The European Medicines Agency has gi...
South Korean drug firm SK Biopharmaceuticals is expected to raise at least 5 trillion won ($4.25 billion) through a planned share sale, analysts said Nov. 25. The company said that XCOPRI has won...
South Korean biotech firm Bridge Biotherapeutics CEO Lee Jung-kyu announced Nov. 22 that the company plans to expand further after going public in December. The company expects to be listed on the s...
SK Biopharmaceuticals said Nov. 22 its anti-epileptic drug has won approval from the US Food and Drug Administration. The company said the FDA granted approval of XCOPRI, or cenobamate tablets, f...
South Korea’s Samsung Bioepis said Nov. 20 that the US Food and Drug Administration has started reviewing its application for sales of SB8, a proposed biosimilar referencing Avastin. Samsung Group’s...
SK Biopharm announced on Nov. 18 that its narcolepsy drug Sunosi received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). Narcolepsy is...
Celltrion Pharm, the generic arm of Celltrion, announced Nov. 14 that its sales jumped 36.6 percent in the third quarter from a year earlier to 47.43 billion won ($40.7 million). The South Korean co...
Samsung Biologics announced Nov. 14 that it has received 27001 security certification from the Geneva-based International Organization for Standardization. The company emphasized that it is the firs...
Korean biotech firm Hugel announced Nov. 12 that its operating profit jumped 225 percent in the third quarter from a year earlier to 18.2 billion won ($15.57 million). Its sales increased by 46.4 pe...
GOTTINGEN, Germany -- Behind the market expansion of Samsung’s biologics business is 149-year-old Sartorius, a German firm that has helped it grow rapidly. Founded in 1870, the German company suppli...
South Korean pharmaceutical firm Samsung Bioepis said Nov. 7 it has entered into a new commercialization agreement worth $370 million with US partner Biogen. Under the partnership, Biogen will be...
Celltrion announced on Nov. 5 that it will start phase 3 clinical trials of its patch-type donepezil, a medication that aims to treat people with Alzheimer’s disease, jointly with local drugmaker Icu...
Bio company SillaJen announced Oct. 31 it will pay back 110 billion won (94.25 million), which it received by issuing convertible bonds, to Kiwoon Securities in March. “The annual interest rate for ...
South Korea’s Health Ministry said Oct. 30 that it is considering revoking Kolon Life Science’s innovative drug company certification for mislabeling and falsely reporting ingredients in its gene the...
Sales of biosimilar Remsima by South Korean bio-pharmaceutical firm Celltrion reached $77 million in the United States during the third quarter of this year, industry data showed Oct. 30. Sales o...
[Market Close-up] S. Korean stock market recovers faster than other markets
One Equity Partners to unload Celltrion Healthcare stake at discount
Local telecom firms bid for fifth-largest cable TV operator Hyundai HCN
IBK fined $86m in US over mishandling anti-money laundering program
Acleda Bank lists on KRX-invested Cambodian stock exchange
Samsung Biologics bags CMO deals worth W468b
Tmon vows to turn profit by 10th anniversary
Macrogen’s COVID-19 test kit approved for export
May 28, 2020
![[Market Close-up] S. Korean stock market recovers faster than other markets](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2020/05/27/20200527000702_0.jpg&md=20200527162557)
